Outcomes of second allogeneic stem cell transplantation and anti‐relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis
Second allogeneic stem cell transplantation (allo‐SCT2) represents a rescue option for selected patients (pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML). Still, relapse rates post‐allo‐SCT2 remain high and effective anti‐relapse strategies and predictive biomarkers remain to be def...
Gespeichert in:
| Veröffentlicht in: | Hematological oncology 2022-10, Vol.40 (4), p.763-776 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 776 |
|---|---|
| container_issue | 4 |
| container_start_page | 763 |
| container_title | Hematological oncology |
| container_volume | 40 |
| creator | Shumilov, Evgenii Hasenkamp, Justin Maulhardt, Markus Mazzeo, Paolo Schmidt, Nicole Boyadzhiev, Hristo Jung, Wolfram Ganster, Christina Haase, Detlef Koch, Raphael Wulf, Gerald |
| description | Second allogeneic stem cell transplantation (allo‐SCT2) represents a rescue option for selected patients (pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML). Still, relapse rates post‐allo‐SCT2 remain high and effective anti‐relapse strategies and predictive biomarkers remain to be defined. We here analyzed a cohort of 41 AML patients (pts) undergoing allo‐SCT2 in our center. Allo‐SCT2 induced a third hematologic complete remission (CR) in 37 pts, at costs of a 36% non‐relapse mortality rate. Furthermore, 19 pts eventually relapsed post allo‐SCT2. Addressing relapse after allo‐SCT2, 14 pts (74%) underwent cell‐based anti‐relapse strategies, including third allogeneic transplantation (allo‐SCT3; 3/14), donor lymphocyte infusions (DLIs) combined with either 5‐azacytidin and venetoclax (4/14) or chemotherapeutic agents (7/14). Notably, six of seven pts (86%) who received either allo‐SCT3 or a combination therapy of DLIs, 5‐azacytidine and venetoclax achieved CR despite poor cytogenetics post‐allo‐SCT2 (e.g., TP53). Finally, 11 of 41 pts were alive at the last follow‐up (seven CR2, three CR3, one partial remission) resulting in estimated 2‐ and 5‐year overall survival of 35% and 25%, respectively. |
| doi_str_mv | 10.1002/hon.2995 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2646941349</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2646941349</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3835-f30a929794808f95d1540bb8507894f80fbf154dbdf8022872144517b5e995943</originalsourceid><addsrcrecordid>eNp1kUFu1TAQhi1ERR8FiRMgS2zYpHUc58VmV1VAkaq-Dawjx5m0Lo4dbKdVdhyB03AgTsKEvhYJiZUt-_M34_kJeVWy45IxfnId_DFXqn5CNiVTqijZVj0lG8YbWTBe8UPyPKUbxvCOyWfksKqrrURoQ37u5mzCCImGgSYwwfdUOxeuwIM1NGUYqQHnaI7ap8lpn3W2wVO9gj7bX99_RHB6SoBw1BmuLMqspxNy4HOidzZf0z3Tn0QYojY5xIVqM2eg4wIu2J46mL_CaPU7ekpnbw2-jdhBhBxDmsBkewtYUbsl2fSCHAzaJXi5X4_Ilw_vP5-dFxe7j5_OTi8KU8mqLoaKacVVo4RkclB1X9aCdZ2sWSOVGCQbugGP-q7HPeey4aUQddl0NeA0laiOyNt77xTDtxlSbkeb1nloD2FOLd-KrRJlJRSib_5Bb8IcsV-kVm8jeM3-Cg3-KuEw2inaUcelLVm7Ztlilu2aJaKv98K5G6F_BB_CQ6C4B-6sg-W_ovZ8d_lH-BumSqye</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2721474250</pqid></control><display><type>article</type><title>Outcomes of second allogeneic stem cell transplantation and anti‐relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis</title><source>Wiley Journals</source><creator>Shumilov, Evgenii ; Hasenkamp, Justin ; Maulhardt, Markus ; Mazzeo, Paolo ; Schmidt, Nicole ; Boyadzhiev, Hristo ; Jung, Wolfram ; Ganster, Christina ; Haase, Detlef ; Koch, Raphael ; Wulf, Gerald</creator><creatorcontrib>Shumilov, Evgenii ; Hasenkamp, Justin ; Maulhardt, Markus ; Mazzeo, Paolo ; Schmidt, Nicole ; Boyadzhiev, Hristo ; Jung, Wolfram ; Ganster, Christina ; Haase, Detlef ; Koch, Raphael ; Wulf, Gerald</creatorcontrib><description>Second allogeneic stem cell transplantation (allo‐SCT2) represents a rescue option for selected patients (pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML). Still, relapse rates post‐allo‐SCT2 remain high and effective anti‐relapse strategies and predictive biomarkers remain to be defined. We here analyzed a cohort of 41 AML patients (pts) undergoing allo‐SCT2 in our center. Allo‐SCT2 induced a third hematologic complete remission (CR) in 37 pts, at costs of a 36% non‐relapse mortality rate. Furthermore, 19 pts eventually relapsed post allo‐SCT2. Addressing relapse after allo‐SCT2, 14 pts (74%) underwent cell‐based anti‐relapse strategies, including third allogeneic transplantation (allo‐SCT3; 3/14), donor lymphocyte infusions (DLIs) combined with either 5‐azacytidin and venetoclax (4/14) or chemotherapeutic agents (7/14). Notably, six of seven pts (86%) who received either allo‐SCT3 or a combination therapy of DLIs, 5‐azacytidine and venetoclax achieved CR despite poor cytogenetics post‐allo‐SCT2 (e.g., TP53). Finally, 11 of 41 pts were alive at the last follow‐up (seven CR2, three CR3, one partial remission) resulting in estimated 2‐ and 5‐year overall survival of 35% and 25%, respectively.</description><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.2995</identifier><identifier>PMID: 35368106</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Acute myeloid leukemia ; anti‐relapse strategies beyond allo‐SCT2 ; Azacytidine ; Biomarkers ; Chemotherapy ; Cytogenetics ; donor lymphocyte infusion (DLI) ; Leukemia ; Lymphocytes ; relapsed/refractory acute myeloid leukemia (r/r AML) ; Remission ; Remission (Medicine) ; second allogeneic stem cell transplantation (allo‐SCT2) ; Stem cell transplantation ; Stem cells ; Transplantation ; venetoclax</subject><ispartof>Hematological oncology, 2022-10, Vol.40 (4), p.763-776</ispartof><rights>2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3835-f30a929794808f95d1540bb8507894f80fbf154dbdf8022872144517b5e995943</citedby><cites>FETCH-LOGICAL-c3835-f30a929794808f95d1540bb8507894f80fbf154dbdf8022872144517b5e995943</cites><orcidid>0000-0002-2018-5685 ; 0000-0003-0178-1729</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhon.2995$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhon.2995$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35368106$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shumilov, Evgenii</creatorcontrib><creatorcontrib>Hasenkamp, Justin</creatorcontrib><creatorcontrib>Maulhardt, Markus</creatorcontrib><creatorcontrib>Mazzeo, Paolo</creatorcontrib><creatorcontrib>Schmidt, Nicole</creatorcontrib><creatorcontrib>Boyadzhiev, Hristo</creatorcontrib><creatorcontrib>Jung, Wolfram</creatorcontrib><creatorcontrib>Ganster, Christina</creatorcontrib><creatorcontrib>Haase, Detlef</creatorcontrib><creatorcontrib>Koch, Raphael</creatorcontrib><creatorcontrib>Wulf, Gerald</creatorcontrib><title>Outcomes of second allogeneic stem cell transplantation and anti‐relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis</title><title>Hematological oncology</title><addtitle>Hematol Oncol</addtitle><description>Second allogeneic stem cell transplantation (allo‐SCT2) represents a rescue option for selected patients (pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML). Still, relapse rates post‐allo‐SCT2 remain high and effective anti‐relapse strategies and predictive biomarkers remain to be defined. We here analyzed a cohort of 41 AML patients (pts) undergoing allo‐SCT2 in our center. Allo‐SCT2 induced a third hematologic complete remission (CR) in 37 pts, at costs of a 36% non‐relapse mortality rate. Furthermore, 19 pts eventually relapsed post allo‐SCT2. Addressing relapse after allo‐SCT2, 14 pts (74%) underwent cell‐based anti‐relapse strategies, including third allogeneic transplantation (allo‐SCT3; 3/14), donor lymphocyte infusions (DLIs) combined with either 5‐azacytidin and venetoclax (4/14) or chemotherapeutic agents (7/14). Notably, six of seven pts (86%) who received either allo‐SCT3 or a combination therapy of DLIs, 5‐azacytidine and venetoclax achieved CR despite poor cytogenetics post‐allo‐SCT2 (e.g., TP53). Finally, 11 of 41 pts were alive at the last follow‐up (seven CR2, three CR3, one partial remission) resulting in estimated 2‐ and 5‐year overall survival of 35% and 25%, respectively.</description><subject>Acute myeloid leukemia</subject><subject>anti‐relapse strategies beyond allo‐SCT2</subject><subject>Azacytidine</subject><subject>Biomarkers</subject><subject>Chemotherapy</subject><subject>Cytogenetics</subject><subject>donor lymphocyte infusion (DLI)</subject><subject>Leukemia</subject><subject>Lymphocytes</subject><subject>relapsed/refractory acute myeloid leukemia (r/r AML)</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>second allogeneic stem cell transplantation (allo‐SCT2)</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Transplantation</subject><subject>venetoclax</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kUFu1TAQhi1ERR8FiRMgS2zYpHUc58VmV1VAkaq-Dawjx5m0Lo4dbKdVdhyB03AgTsKEvhYJiZUt-_M34_kJeVWy45IxfnId_DFXqn5CNiVTqijZVj0lG8YbWTBe8UPyPKUbxvCOyWfksKqrrURoQ37u5mzCCImGgSYwwfdUOxeuwIM1NGUYqQHnaI7ap8lpn3W2wVO9gj7bX99_RHB6SoBw1BmuLMqspxNy4HOidzZf0z3Tn0QYojY5xIVqM2eg4wIu2J46mL_CaPU7ekpnbw2-jdhBhBxDmsBkewtYUbsl2fSCHAzaJXi5X4_Ilw_vP5-dFxe7j5_OTi8KU8mqLoaKacVVo4RkclB1X9aCdZ2sWSOVGCQbugGP-q7HPeey4aUQddl0NeA0laiOyNt77xTDtxlSbkeb1nloD2FOLd-KrRJlJRSib_5Bb8IcsV-kVm8jeM3-Cg3-KuEw2inaUcelLVm7Ztlilu2aJaKv98K5G6F_BB_CQ6C4B-6sg-W_ovZ8d_lH-BumSqye</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Shumilov, Evgenii</creator><creator>Hasenkamp, Justin</creator><creator>Maulhardt, Markus</creator><creator>Mazzeo, Paolo</creator><creator>Schmidt, Nicole</creator><creator>Boyadzhiev, Hristo</creator><creator>Jung, Wolfram</creator><creator>Ganster, Christina</creator><creator>Haase, Detlef</creator><creator>Koch, Raphael</creator><creator>Wulf, Gerald</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2018-5685</orcidid><orcidid>https://orcid.org/0000-0003-0178-1729</orcidid></search><sort><creationdate>202210</creationdate><title>Outcomes of second allogeneic stem cell transplantation and anti‐relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis</title><author>Shumilov, Evgenii ; Hasenkamp, Justin ; Maulhardt, Markus ; Mazzeo, Paolo ; Schmidt, Nicole ; Boyadzhiev, Hristo ; Jung, Wolfram ; Ganster, Christina ; Haase, Detlef ; Koch, Raphael ; Wulf, Gerald</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3835-f30a929794808f95d1540bb8507894f80fbf154dbdf8022872144517b5e995943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acute myeloid leukemia</topic><topic>anti‐relapse strategies beyond allo‐SCT2</topic><topic>Azacytidine</topic><topic>Biomarkers</topic><topic>Chemotherapy</topic><topic>Cytogenetics</topic><topic>donor lymphocyte infusion (DLI)</topic><topic>Leukemia</topic><topic>Lymphocytes</topic><topic>relapsed/refractory acute myeloid leukemia (r/r AML)</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>second allogeneic stem cell transplantation (allo‐SCT2)</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Transplantation</topic><topic>venetoclax</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shumilov, Evgenii</creatorcontrib><creatorcontrib>Hasenkamp, Justin</creatorcontrib><creatorcontrib>Maulhardt, Markus</creatorcontrib><creatorcontrib>Mazzeo, Paolo</creatorcontrib><creatorcontrib>Schmidt, Nicole</creatorcontrib><creatorcontrib>Boyadzhiev, Hristo</creatorcontrib><creatorcontrib>Jung, Wolfram</creatorcontrib><creatorcontrib>Ganster, Christina</creatorcontrib><creatorcontrib>Haase, Detlef</creatorcontrib><creatorcontrib>Koch, Raphael</creatorcontrib><creatorcontrib>Wulf, Gerald</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shumilov, Evgenii</au><au>Hasenkamp, Justin</au><au>Maulhardt, Markus</au><au>Mazzeo, Paolo</au><au>Schmidt, Nicole</au><au>Boyadzhiev, Hristo</au><au>Jung, Wolfram</au><au>Ganster, Christina</au><au>Haase, Detlef</au><au>Koch, Raphael</au><au>Wulf, Gerald</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes of second allogeneic stem cell transplantation and anti‐relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis</atitle><jtitle>Hematological oncology</jtitle><addtitle>Hematol Oncol</addtitle><date>2022-10</date><risdate>2022</risdate><volume>40</volume><issue>4</issue><spage>763</spage><epage>776</epage><pages>763-776</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><abstract>Second allogeneic stem cell transplantation (allo‐SCT2) represents a rescue option for selected patients (pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML). Still, relapse rates post‐allo‐SCT2 remain high and effective anti‐relapse strategies and predictive biomarkers remain to be defined. We here analyzed a cohort of 41 AML patients (pts) undergoing allo‐SCT2 in our center. Allo‐SCT2 induced a third hematologic complete remission (CR) in 37 pts, at costs of a 36% non‐relapse mortality rate. Furthermore, 19 pts eventually relapsed post allo‐SCT2. Addressing relapse after allo‐SCT2, 14 pts (74%) underwent cell‐based anti‐relapse strategies, including third allogeneic transplantation (allo‐SCT3; 3/14), donor lymphocyte infusions (DLIs) combined with either 5‐azacytidin and venetoclax (4/14) or chemotherapeutic agents (7/14). Notably, six of seven pts (86%) who received either allo‐SCT3 or a combination therapy of DLIs, 5‐azacytidine and venetoclax achieved CR despite poor cytogenetics post‐allo‐SCT2 (e.g., TP53). Finally, 11 of 41 pts were alive at the last follow‐up (seven CR2, three CR3, one partial remission) resulting in estimated 2‐ and 5‐year overall survival of 35% and 25%, respectively.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>35368106</pmid><doi>10.1002/hon.2995</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-2018-5685</orcidid><orcidid>https://orcid.org/0000-0003-0178-1729</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0232 |
| ispartof | Hematological oncology, 2022-10, Vol.40 (4), p.763-776 |
| issn | 0278-0232 1099-1069 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2646941349 |
| source | Wiley Journals |
| subjects | Acute myeloid leukemia anti‐relapse strategies beyond allo‐SCT2 Azacytidine Biomarkers Chemotherapy Cytogenetics donor lymphocyte infusion (DLI) Leukemia Lymphocytes relapsed/refractory acute myeloid leukemia (r/r AML) Remission Remission (Medicine) second allogeneic stem cell transplantation (allo‐SCT2) Stem cell transplantation Stem cells Transplantation venetoclax |
| title | Outcomes of second allogeneic stem cell transplantation and anti‐relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T08%3A56%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20of%20second%20allogeneic%20stem%20cell%20transplantation%20and%20anti%E2%80%90relapse%20strategies%20in%20patients%20with%20relapsed/refractory%20acute%20myeloid%20leukemia:%20A%20unicentric%20retrospective%20analysis&rft.jtitle=Hematological%20oncology&rft.au=Shumilov,%20Evgenii&rft.date=2022-10&rft.volume=40&rft.issue=4&rft.spage=763&rft.epage=776&rft.pages=763-776&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.2995&rft_dat=%3Cproquest_cross%3E2646941349%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2721474250&rft_id=info:pmid/35368106&rfr_iscdi=true |